This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Sheldon Feldman, Montefiore Medical Center
Sponsor:
Information provided by (Responsible Party):
Sheldon Feldman, Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT02127073
First received: April 28, 2014
Last updated: February 12, 2017
Last verified: February 2017
April 28, 2014
February 12, 2017
March 2014
March 2018   (Final data collection date for primary outcome measure)
Percentage of patients with detection of microRNA in NAF, serum, or tissue [ Time Frame: 3 years ]
Same as current
Complete list of historical versions of study NCT02127073 on ClinicalTrials.gov Archive Site
Percentage of patients with collection of ≥ 5 μL of nipple aspirate fluid [ Time Frame: 3 years ]
Same as current
Not Provided
Not Provided
 
Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer
Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer
The purpose of this study is to examine the genetic material called microRNA of three types of specimens from women with breast cancer. The study also seeks to examine the effectiveness of using a new agent called oxytocin to increase the amount of nipple fluid that can be collected during surgery.
Vast majority of breast cancers arise from ductal epithelium. Ductal cells can be collected through the nipple orifice very early in breast cancer development. The nipple aspirate fluid (NAF) can be used to identify biomarkers that predict risk of breast cancer. To date, the biomarkers identified in nipple aspirate fluid (NAF) have limited utility due to the large volume of NAF required for data analysis. Recent studies show intranasal oxytocin's utility in enhancing the yield of nipple aspirate fluid (NAF) among healthy, non-lactating female patients as well as those at high risk for breast cancer. This capability is crucial for the analysis of various markers associated with breast disease and cancer such as microRNAs. The primary aim of the study is to determine whether the microRNA profile characterization is feasible with the collection of tissue, serum and NAF in patients with in situ and invasive breast cancer. Intranasal oxytocin will be used to enhance fluid yielding of the NAF.
Interventional
Early Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
  • Breast Cancer
  • Ductal Carcinoma in Situ
Drug: Intranasal Oxytocin
Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
Other Name: Syntocinon Spray
Experimental: Oxytocin
Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
Intervention: Drug: Intranasal Oxytocin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
March 2019
March 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer
  • Candidate for breast conserving surgery or mastectomy

Exclusion Criteria:

  • Pregnant women
  • Prior Breast Cancer diagnosis
  • Adverse reaction to Oxytocyn in the past
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact: Sheldon M Feldman, MD (212) 305-9676
United States
 
 
NCT02127073
AAAL5203
Yes
Not Provided
Plan to Share IPD: Undecided
Sheldon Feldman, Montefiore Medical Center
Sheldon Feldman
Not Provided
Principal Investigator: Sheldon Feldman, MD Columbia University
Montefiore Medical Center
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP